阿加曲班在不同条件下治疗急性脑梗死的疗效差异

Clinical efficacy of argatroban in the treatment of acute cerebral infarction under different conditions

目的探讨阿加曲班治疗急性脑梗死的临床疗效,比较不同条件下阿加曲班的临床效果差异。方法随机选择2014年1-12月我院收治的急性脑梗死患者193例,所有患者均给予常规抗血小板及静脉改善循环药物治疗,其中住院期间使用阿加曲班患者92例(观察组),未使用阿加曲班患者101例(对照组)。记录两组患者用药14 d后的NIHSS评分,比较其临床效果及不良反应。比较不同年龄、性别、发病部位及用药时间下NIHSS评分的差异。结果用药后14 d观察组的NIHSS评分低于对照组(P<0.05);观察组NIHSS评分减少值明显高于对照组(P<0.05)。两组均无明显不良反应。不同年龄、性别、卒中部位及用药时间的患者治疗效果未见明显区别。结论阿加曲班可改善急性脑梗死患者的预后,有较高的安全性,适合不同部位、不同性别、不同年龄的急性脑梗死患者,在12 h后开始用药仍有确切疗效。

Objective To explore the clinical effect of argatroban on acute cerebral infarction under different condition.Methods A total of 193 acute cerebral infarction cases who accepted treatment from January to December 2014 were randomly selected in our hospital retrospectively.All the patients recieved regular anti-platelet treatment and improve circulation therapy,and the patients in treatment group（n =92） were injected with argatroban,patients in control group（n = 101） did not accept argatroban treatment NIHSS scores at 14 d after medication,clinical efficacy and adverse reaction were compared between the two groups,and NIHSS scores of patients under different condition were compared too.Results NIHSS score at 14 d after medication in treatment group was lower than that of control group（P 〈0.05）,and there was signficant difference in the decrease of NIHSS score between the two groups（P 〈0.05）.No obvious adverse reaction was found in the two groups.There was no significant difference in clinical efficacy among the patients with different age,sex,location and medication time.Conclusion Argatroban can improve the prognosis of patients with acute cerebral infarction with high security,the treatment is suitalble for the acute cerebral infarction patients with different location of infarcion,different sex or age,and the efficacy remains definite at 12 h after medication.